Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668784 · ClinicalTrials.gov registry record · Phase 3
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 821
- Enrollment target
NCT01668784 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 821 participants.
The verdict
NCT01668784, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 821 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Interventions
- DRUG Everolimus
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 821 participants |
| Start Date | 2012-10-09 |
| Est. Completion | 2021-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01668784
The ClinicalTrials.gov registry entry for NCT01668784 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 821 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01668784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01668784 about?
NCT01668784 is a clinical study titled "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)". The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
What is the current status of trial NCT01668784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 821 participants. The study started on 2012-10-09. Estimated completion is 2021-07-19.
What interventions are being tested in trial NCT01668784?
The interventions under investigation include: Everolimus (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01668784?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.